Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541187 · ClinicalTrials.gov registry record · Phase 2
Cockroach Immunotherapy in Children and Adolescents
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT03541187 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 82 participants.
The verdict
NCT03541187, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma. Therefore, a major goal of the Inner City Asthma Consortium (ICAC) is to evaluate the efficacy of cockroach immunotherapy in inner city asthma. The primary objective of the study is to determine if the response to nasal allergen challenge (NAC) will be changed with treatment with cockroach subcutaneous immunotherapy (SCIT) treatment.
Interventions
- BIOLOGICAL German cockroach allergenic extract
- BIOLOGICAL Placebo for German cockroach allergenic extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2022-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03541187
The ClinicalTrials.gov registry entry for NCT03541187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which German cockroach allergenic extract is the first listed.
NCT03541187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03541187 about?
NCT03541187 is a clinical study titled "Cockroach Immunotherapy in Children and Adolescents". Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma. Therefore, a major goal of the Inner City...
What is the current status of trial NCT03541187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2018-07-16. Estimated completion is 2022-06-03.
What interventions are being tested in trial NCT03541187?
The interventions under investigation include: German cockroach allergenic extract (BIOLOGICAL), Placebo for German cockroach allergenic extract (BIOLOGICAL).
Who is sponsoring clinical trial NCT03541187?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.